Small Airways Disease in Asymptomatic and Symptomatic Subjects With Airway Hyperresponsiveness (AHR)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-05-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to study differences in small airways (\<2mm) parameters in asthma patients, subjects with asymptomatic airway hyperresponsiveness and healthy controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inflammatory Processes in the Airway of Asthmatics With Persistent Bronchial Hyperreactivity

NCT00217854

Asthma

COMPLETED NA

Therapeutic Relevance of Abnormal Airway Morphology in Asthma

NCT06970080

Asthma

RECRUITING PHASE4

Azithromycin and Oesophageal Function in Respiratory Disease

NCT05469555

Cough Asthma Copd +1 more

COMPLETED

Effects of Regular Submaximal Exercise on Asthma Control and Quality of Life in Patients With Persistent Symptoms

NCT04395937

Chronic Asthma

UNKNOWN NA

Clinical Relevance of Small Airways Disease in Severe Asthma Patients Treated With Anti-InterLeukin-5 Therapy

NCT05706597

Asthma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma Airway Hyperresponsiveness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asthma

asthmatic subjects

No interventions assigned to this group

Asymptomatic AHR

Asymptomatic subjects with airway hyperresponsiveness

No interventions assigned to this group

Control

Healthy controls, without airway hyperresponsiveness

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 65 years.
* Forced expiratory volume in one second (FEV1) \> 80% predicted post bronchodilator.
* Provocative concentration causing a 205 fall in FEV1 (PC20) methacholine \<8 mg/ml.
* No history of asthma or previous use of asthma medication.

* Age between 18 and 65 years.
* FEV1 \> 80% predicted post bronchodilator.
* PC20 methacholine \>8 mg/ml.
* No history of asthma or previous use of asthma medication.

* Age between 18 and 65 years.
* FEV1 \> 80% predicted.
* PC20 methacholine ≤8 mg/ml.
* Doctor's diagnosis of asthma.
* No history of Chronic obstructive pulmonary disease (COPD).

Exclusion Criteria

* Use of inhaled or oral steroids, antihistamines, nedocromil, theophylline, leukotrien antagonists or long-acting beta-agonists for at least three weeks before the start of the study.
* Any disease that may affect the outcome of the study as judged by the Investigator.
* FEV1 \<1.2 liter.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes